Evaluation of Multifocal Contact Lens Designs With and Without an HEV Blocker on Visual Function

NCT04995055 | Completed Results FDA Device

• 1 other identifier: CR-6391
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-masked, bilateral, controlled, randomized, 2x2 crossover, non-dispensing clinical trial to characterize the effects of an HEV-Blocker on several measures of visual function in a presbyopic population.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (3)

• Starburst Diameter (mm)

  The starburst diameter (mm) was measured each subject binocularly. Starburst diameter was quantified by the horizontal spread of the spokes emerging from the center of a small, point-like stimulus. A calibrated custom-made micrometer (two sides with reverse threading) was used to spread two posts out from a central mid-point. The posts attach to a custom-designed ruler that indicates the lateral spread of the starburst. Measurements for this metric are positive. Smaller diameter indicates better lens performance. The average diameter (mm) for each lens type was reported by period.

  30-minutes post lens insertion

• Halos Diameter (mm)

  Halo diameter (mm) was quantified and measured using the same micrometer as for starbursts diameter (mm). The Halo diameter (mm) was measured each subject binocularly. Measurements for halo diameter are positive, where smaller values indicate better performance. The average diameter (mm) for each lens type.

  30-minutes post lens insertion

• Glare Disability Threshold

  Glare disability threshold was collected binocularly for each subject. Subjects were exposed to a target stimulus for 2 seconds; before the measurement was taken the annulus was set to a level below that which would cause the target stimulus to be veiled. The experimenter would then adjust the intensity of the annulus until subjects could no longer see the target stimulus. Subjects would indicate this by pressing a buzzer. Glare disability thresholds take on positive values, where higher values indicate better lens performance. The average glare disability level (change in log relative energy) for each lens type was reported.

  30-minutes post lens insertion

Secondary Outcomes (4)

• Glare Discomfort (mm)

  30-minutes post lens insertion

• Heterochromatic Contrast Threshold (HCT)

  30-minutes post lens insertion

• Two-Point Threshold (mm) With 403nm Filter

  30-minutes post lens insertion

• Two-Point Threshold (mm) Without 403nm Filter

  30-minutes post lens insertion

Study Arms (2)

Period 1

EXPERIMENTAL

Eligible subjects will be randomly assigned to contact lens wear sequence TEST/CONTROL in a bilateral fashion.

Device: JJVC Investigational Multifocal Contact Lens TEST Lens; Device: ACUVUE® OASYS Multifocal

Period 2

EXPERIMENTAL

Eligible subjects will be randomly assigned to contact lens wear sequence CONTROL/ TEST in a bilateral fashion.

Device: JJVC Investigational Multifocal Contact Lens TEST Lens; Device: ACUVUE® OASYS Multifocal

Interventions

JJVC Investigational Multifocal Contact Lens TEST Lens DEVICE

TEST Lens

Period 1; Period 2

ACUVUE® OASYS Multifocal DEVICE

CONTROL Lens

Period 1; Period 2

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:
• Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Be between at least 40 and not more than 70 years of age at the time of screening.
• Possess a wearable pair of spectacles that provide correction for distance vision.
• Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
• Be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
• The subject must have normal color perception as evidenced by reading 17 out of the first 21 Ishihara plates correctly.
• The subject's distance spherical equivalent of their refraction must be in the range of -1.00 D to -4.00 D.
• The subject's refractive cylinder must be ≤0.75 D in each eye.
• The subject's ADD power must be in the range of +0.75 D to +2.50 D in each eye.
• The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Be currently pregnant or lactating.
• Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
• Use of any of the following oral medications within 1 week prior to enrollment: oral retinoids, oral tetracyclines, oral phenothiazines, anticholinergics, oral/inhaled steroids, oral phosphodiesterase type 5 inhibitors, interferon alfa, antimycobacterial antibiotics, and nitroimidazole antibiotics. See Section 9.1 for additional details regarding excluded systemic medications.
• Any current use of ocular medication with the exception of rewetting drops.
• Any known hypersensitivity or allergic reaction to single use preservative free rewetting drops or sodium fluorescein.
• Any previous or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK dacryocystorhinostomy, cataract surgery, retinal surgery, peripheral iridotomy/iridectomy, etc.).
• Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
• Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
• Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
• A history of amblyopia, strabismus or binocular vision abnormality.
• History of optic nerve or retinal disease or trauma
• Abnormal color vison.
• Any other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or corneal distortion
• Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA scale.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (1)

University of Georgia

Athens, Georgia, 30602, United States

Location

Results Point of Contact

• Title: Thomas R. Karkkainen, OD, MS, FAAO
• Organization: Johnson & Johnson Vision Care, Inc. (JJVC)

TKarkkai@its.jnj.com

1-800-843-2020

Study Officials

• Johnson & Johnson Vision Care, Inc. Clinical Trial

  Johnson & Johnson Vision Care, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 29, 2021
• First Posted: August 6, 2021
• Study Start: October 25, 2021
• Primary Completion: April 14, 2022
• Study Completion: April 14, 2022
• Last Updated: June 6, 2023
• Results First Posted: June 6, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will share

Locations

US (1)